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vitro radiosensitivity of tumour specimens (Brock et al, 1990;
Eschwege et al, 1997) or derived cell lines (Allanunis-Turner et al,
1992; Ramsay et al, 1992; Taghian et al, 1993), measured by the
overall SF, and the clinical outcome of individual patients after
curative radiotherapy in any tumour type.
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Reply to the letter from B Stausb0olGr0n et al
Sir,
The above letter reports the predominant growth of fibroblasts
rather than tumour cells in soft agar cultures ofcervix carcinomas.
It then suggests that results generated by my co-workers and I
(West et al, 1997) show that 'it may be likely that' fibroblast
radiosensitivity predicts clinical outcome after radiotherapy in
cervix cancer (Stausb0l-Gr0n et al, 1998). There are four reasons
why I believe they cannot translate their experience to our results.
First, there is the issue of antibody cross-specificity. This
problem is most clearly demonstrated from a study on human lung
tumours cultured in soft agar (Lawton et al, 1995). In the worst case,
three of four colonies examined showed positive staining with
cytokeratin markers and eight of eight colonies showed positive
staining with a fibroblast marker (5B5). That is, for the same
tumour, 75% of the colonies grown were tumour marker positive
and 100% were fibroblast marker positive. The 5B5 monoclonal
antibody stains prolyl 4-hydroxylase, which is involved in collagen
synthesis and has been reported to be specific for fibroblasts
(Esterre et al, 1992). However, both human endothelial
(Schwachula et al. 1994) and macrophage (Labat et al, 1991) cells
have been shown to express 5B5. Although, to my knowledge, it
has not been studied in tumours, it is possible that some will express
5B5. The cervix tumour work of Stausb0l-Gr0n and co-workers
(1998) used the anti-vimentin monoclonal antibody 3B4 as a
marker for fibroblast cells. Unfortunately, vimentin expression is
not fibroblast specific. Vimentin expression in tumour cells may be
a feature of dedifferentiation, and it has been reported for a variety
of tumour types: breast tumours (Gould et al, 1990), sarcomas
(Gerharz et al, 1990), carcinomas of the vulva (Weikel et al, 1996),
lung carcinomas (Blobel et al, 1984) and endometrial carcinomas
(Mobus et al, 1993). In addition, in a series offourcervix carcinoma
lines, two squamous cell carcinomas were shown to be positive for
vimentin expression (Kelland et al, 1987). To complicate the situa-
tion further, tumours can not only express vimentin but they can
also lose keratin expression during cell division (Lane et al, 1982)
and culture (Mackay et al, 1990). In support ofthis, rapidly prolifer-
ating tumours have been shown to have a lower proportion ofcytok-
eratin-positive tumour cells (Wingren et al, 1995).
In our own work, we have looked at low-molecular-weight
cytokeratin expression in some cervix tumours (Davidson et al,
1992). Nine tumours were examined using CAM5.2 (recognizing
cytokeratins 8, 18 and 19) and CKI (recognizing cytokeratins 6
and 18) antibodies, and positive staining of colonies was seen.
Although the majority was positive using both stains, two tumours
were CAM5.2 positive and CK1 negative, showing the importance
of using multiple cytokeratin markers.
Secondly, there is a difference in the method used by the Aarhus
and Manchester groups. In culturing human tumours, we use an
enzyme cocktail followed by a half-hour disaggregation in trypsin
(omitted by the Aarhus group), which is used at a fivefold higher
concentration than used for the routine subculture of monolayer
cells. Trypsin is known to be toxic to fibroblasts and must be used
at a low concentration for a short period of time. Indeed, selective
trypsinization is used in establishing epithelial cultures to prevent
overgrowth by fibroblasts (e.g. Schumann et al, 1988). In addition,
we have quantified the cell types present in cell suspensions
prepared using enzymes from cervix tumours (Davidson et al,
1992). The predominant cell type present is tumour (mean 45%)
followed by granulocyte (mean 24%), lymphocyte (mean 16%)
and macrophage (mean 15%). Fibroblast-like cells are seen rarely.
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Figure 1 The relationship between colony-forming efficiency (CFE) and outcome in 128 cervix carcinomas treated with radiotherapy. Patients were stratified
according to the median value of CFE (0.06%), which was obtained before treatment using a soft agar clonogenic assay. The lower arm represents patients with
tumour CFE greater than the median. Follow-up times ranged from 2 to 5 years with a median of 47 months. The P-values are the results of univariate log-rank
analyses
Thirdly, there is circumstantial evidence from our data that
supports the fact that predominantly tumour colonies grow in agar.
The ability of tumours to grow in agar is measured as colony-
forming efficiency (CFE) which is considered to reflect tumour
stem cell content. Despite the errors involved in measuring CFE
(Davidson et al, 1990), it is a significant prognostic factor for local
control after radiotherapy (Figure 1). There is no reason why
fibroblast CFE would predict local recurrence or reflect tumour
stem cell content.
Finally, measurements of fibroblast SF, commonly range from
0.15 to 0.40 (Dahlberg et al, 1993; Burnet et al, 1994). This
contrasts with the higher range of values reported for 'fibroblasts'
from cervix tumours (range 0.28-1.00), which is more compatible
with the range expected for tumour cells
As described above, we believe that the evidence strongly
supports the proposition that we are growing predominantly
tumour and not fibroblast colonies. However, the suggestion has
been made by Stausb0l-Gr0n and co-workers (1998) that we are
probably measuring fibroblast radiosensitivity, which is then an
independent prognostic factor for the response of cervix tumours
to radiotherapy. There are two analyses that may help clarify this
issue. One would be to examine fibroblast radiosensitivity in rela-
tion to treatment outcome in the Aarhus series of breast cancer
patients (Johansen et al, 1996). The other would be the Aarhus
correlations of fibroblast/tumour radiosensitivity with clinical
outcome, which, if they are accurately identifying fibroblast
colony contamination with their selective assessment method,
should improve the value ofSF2 measurements of primary tumour
biopsies in cancer of the cervix.
C West
Section ofGenome Damage and Repair, Paterson Institute of
Cancer Research, Christie Hospital, Wilmslow Road,
Manchester M20 4BX, UK
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Bcl2/Bax ratios in chronic lymphocytic leukaemia and
their correlation with in vitro apoptosis and clinical
resistance
Sir,
We were interested to read the recent article by Pepper et al (Br J
Cancer 76: 935-938, 1997). This paper discussed flow cytometric
quantitation of apoptosis as a measure of responsiveness to
chemotherapy in B-cell chronic lymphocytic leukaemia (B-CLL),
with particular reference to Bcl-2/Bax protein ratios. Our group,
using the same antibodies, is pursuing very similar research in
superficial bladder cancer. We have compared percentages ofposi-
tively staining Bcl-2 and Bax tumour cells before and after in vitro
exposure to mitomycin C in bladder tumours. We have obtained
results (unpublished) which would further support the theory that
Bax dysregulation plays an important role in chemoresistant
tumours (Boersma et al, 1997; Chresta et al, 1996).
As the next stage to our own experiments, we would be very
keen to investigate co-expression of Bcl-2 and Bax in the
bladder tumour cells using flow cytometry. Co-expression
would indicate the extent of heterodimerization of Bcl-2 with
Bax that is likely to affect the inhibition of apoptosis after
chemotherapy (Yang et al, 1995). We were therefore very inter-
ested to read the authors' description of a triple-colour flow
cytometry methodology in B-CLL cells. They described how
they sequentially incubated the cells with anti-CD19 Cy5 PE-
conjugated antibody, Bcl-2 FITC and Bax followed by PE-
labelled secondary antibody. Unfortunately, the authors did not
report their findings on the co-expression of Bcl-2 and Bax in the
B-CLL cells.
Secondly, the paper did not report the Bcl-2 and Bax protein
levels in their clinically untreated patient samples after in vitro
exposure to chlorambucil. Considering our own findings, which
showed a correlation between apoptotic index > 10% and
increased Bax protein, these data would have been very relevant.
Thirdly, we were confused by the fact that the authors confirmed
that the Annexin V-positive Iymphocytes cells were apoptotic by
morphological assessment. Annexin V binds to cells in the early
stages ofapoptosis, are not all likely to exhibit the classical features
of apoptosis (Martin et al, 1995). It would be interesting to know
what criteria the authors used to confirm that the Annexin V-posi-
tive lymphocytes were or were not in early apoptosis.
In summary, the authors designed an important study, but unfor-
tunately they did not exploit or report all oftheir data.
KE Williamson', JD Kelly2, PWHamilton', D McManus'
and SR Johnston2
Departments of'Pathology and2Surgery; The Queen's University
ofBelfast, Northern Ireland, UK
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Bcl2/Bax ratios in chronic lymphocytic leukaemia and
their correlation with in vitro apoptosis and clinical
responsiveness - reply
Sir,
The quantification of Bcl-2 and Bax proteins was achieved by
triple-colour analysis as described in our paper, and the co-expres-
sion of Bcl-2 and Bax was measured in these experiments.
However, our data relate to protein expression in the total gated
B-lymphocyte population of cells rather than to individual cell
analysis; all gated cells expressed both Bcl-2 and Bax proteins.
The index we used to describe this co-expression was a ratio ofthe
two proteins (Bcl-2/Bax) as there is evidence that the ratio ofdeath
promoters to death inhibitors within the cell may determine
susceptibility to death signals (Korsmeyer et al, 1993; Thomas
et al, 1996; Pepper et al, 1996). These ratios were calculated as
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